4.41 USD
▲+0.07+5.00%
2026-08-03
市值
$346.28M
市盈率
—
EPS
-1.33
股息率
—
52 周区间
3.99 – 10.99
成交量
917.01K
Beta
1.47
目标价
20.89
52W 低 3.9952W 高 10.99
价格走势
公司简介
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr...